Cargando…
Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
Autores principales: | Hoch, Jeffrey S., Beca, Jaclyn, Sabharwal, Mona, Livingstone, Scott W., Fields, Anthony L. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519630/ https://www.ncbi.nlm.nih.gov/pubmed/25939500 http://dx.doi.org/10.1007/s40273-015-0278-7 |
Ejemplares similares
-
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
por: Masucci, Lisa, et al.
Publicado: (2017) -
Does electronic economics matter to financial technology firms?
por: Najaf, Khakan, et al.
Publicado: (2022) -
Does it matter for the radiologists’ performance whether they read short or long batches in organized mammographic screening?
por: Backmann, Heinrich A., et al.
Publicado: (2021) -
Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?
por: Cheung, Matthew C, et al.
Publicado: (2017) -
Whether Economic Freedom Is Significantly Related to Death of COVID-19
por: Chen, Ray-Ming
Publicado: (2020)